| Ultra
high throughput screening - Asset |
| |
Asset
is a fully integrated, ultra high throughput screening
system that can process a plate every 30 seconds,
with one operator using any assay technology. |
| |
Asset offers a unique
combination of ultra high throughput screening flexibility,
assay quality (Z') and throughput. |
| |
Asset is operational
at major pharmaceutical sites, including GlaxoSmithKline
and AstraZeneca, routinely screening large compound
libraries against a wide range of assay types. |
| Asset
automates: |
| |
- Ultra high throughput screening (uHTS)
- Batch sizes in excess of 400 plates with lids
(96, 384 or 1536 well) using PlateSafes
- Reagent addition using temperature controlled
reservoirs with optional gassing and agitation
- Tip washing and drying, in parallel with
pipetting
- Tissue culture quality incubation with CO2
and humidity control
- Finely controlled plate washing for cell-based,
coated-well and ELISA procedures
- Signal detection using multiple readers of
user’s choice
- Complete sample tracking giving full audit
trail
- Unlimited multi-stream transfers between compound,
cell and assay plates within an assay
|
| Asset
offers: |
| |
- Processing capacity to handle all likely
workloads - screens 250,000 compounds in 8 hours,
to meet peak demands and complete high priority
screens quickly
- Consistent and reproducible results for even
complex multi-stream ultra high throughput screening
assays - using Asset’s proprietary plate
indexing system
- Flexibility to assemble and measure the full
range of assays – ELISAs, as well as sensitive
cell-based assays
- Rapid and simple changeover between different
assays
- Reliable, unattended operation enables extended-hours
runs
- Choice of user-specified assay technology
and plate readers
|
| |
Asset’s unique
processing style delivers optimised Z’ values
at uHTS throughputs, regardless of assay format.
This enables screening groups to deliver enhanced
service to their clients in therapeutic areas. |
| |
|
